CUE

Cue Biopharma, Inc. (NASDAQ:CUE) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Imagen Biopharma, Inc., the company changed its name to Cue Biopharma in October 2016 and went public in January 2018. The company focuses on developing innovative biologic drugs that selectively modulate the human immune system to treat cancers, chronic infectious diseases, and autoimmune disorders through its proprietary Immuno-STAT platform technology.